CEO Amir Nashat, who has decades of experience in biotech at Polaris Partners, describes the work Soufflé has been doing to catalogue often rare targets and design ligands that carry payloads to them such as siRNAs and ASOs. The company plans to be in the clinic next year and is starting out with muscle conditions.
See link for video.
BOSTON, MA, OCTOBER 13, 2026 — SOUFFLÉ THERAPEUTICS, INC. (“Souffle™” or “Company”), a leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives, today announced the close of an oversubscribed $135...
CAMBRIDGE, MA / ACCESS Newswire / October 2, 2026 / ISEE, a leader in AI-powered autonomous yard operations, today announced a strategic partnership with Holman, a global automotive services organization, to accelerate the commercialization and large-scale deployment...